Pravastatin prevents myocardium from ischemia-induced fibrosis by protecting vascular endothelial cells exposed to oxidative stress

Cardiovascular Drugs and Therapy

Volumn 20, Issue 4, 2006, Pages 273-280

  Abe, Yuichi ^a   Izumi, Takehiko ^a   Urabe, Akihiro ^a   Nagai, Makoto ^a   Taniguchi, Ikuo ^a   Ikewaki, Katsunori ^a   Mochizuki, Seibu ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; eNOS; Myocardial fibrosis; Oxidative stress; Pravastatin

Indexed keywords

CASPASE 3; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROGEN PEROXIDE; PRAVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FIBROSING ALVEOLITIS; HEART DISEASE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HISTOCHEMISTRY; ISCHEMIC HEART DISEASE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FIBROSIS; HEART; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIUM; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PRAVASTATIN; RATS; RATS, WISTAR;

EID: 33750693950     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-006-9525-7     Document Type: Article

References (31)

1. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
2. Scandinavian Simvastatin Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
4. Laufs U, Liao JK. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 2000;10:143-8.
5. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA eductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997;30:1212-7.
6. Kluft C, de Maat MP, Gevers Leuven JA, Potter van Loon BJ, Mohrschladt MF. Statins and C-reactive protein. Lancet 1999;353:1274.
7. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999;99:3227-33.
8. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999;100:178-84.
9. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001;104:982-5.
10. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, Wen J, Takeshita A. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002;105:868-73.
11. Nahrendorf M, Hu K, Hiller KH, Galuppo P, Fraccarollo D, Schweizer G, Haase A, Ertl G, Bauer WR, Bauersachs J. Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction: an experimental serial cardiac magnetic resonance imaging study. J Am Coll Cardiol 2002;40:1695-700.
12. Tokoro T, Wang J, Kitajima I. The novel HMG-CoA reductase inhibitor, Pitavastatin, induces a protective action in vascular endothelial cells through the production of nitric oxide (NO). Yakugaku Zasshi 2004;124:121-6.
13. Izumi T, Saito Y, Kishimoto I, Harada M, Kuwahara K, Hamanaka I, Takahashi N, Kawakami R, Li Y, Takemura G, Fujiwara H, Garbers DL, Mochizuki S, Nakao K. Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-kappaB activation and alleviates myocardial ischemia/reperfusion injury. J Clin Invest 2001;108:203-13.
14. Brandes RP, Fleming I, Busse R. Endothelial aging. Cardiovasc Res 2005;66:286-94.
15. Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 2004;122:339-52.
16. Bezerra DG, Mandarim-de-Lacerda CA. Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodelling and glomeruli loss in spontaneously hypertensive rats. Clin Sci (Lond) 2005;108:349-55.
17. Fornes P, Richer C, Pussard E, Heudes D, Domergue V, Giudicelli JF. Beneficial effects of trandolapril on experimentally induced congestive heart failure in rats. Am J Cardiol 1992;70:43D-51D.
18. Richer C, Mulder P, Fornes P, Domergue V, Heudes D, Giudicelli JF. Long-term treatment with trandolapril opposes cardiac remodeling and prolongs survival after myocardial infarction in rats. J Cardiovasc Pharmacol 1992;20:147-56.
19. Milavetz JJ, Raya TE, Johnson CS, Morkin E, Goldman S. Survival after myocardial infarction in rats: captopril versus losartan. J Am Coll Cardiol 1996;27:714-9.
20. Richer C, Fornes P, Cazaubon C, Domergue V, Nisato D, Giudicelli JF. Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats. Cardiovasc Res 1999;41:100-8.
21. Mitani H, Bandoh T, Ishikawa J, Kimura M, Totsuka T, Hayashi S. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. Br J Pharmacol 1996;119:1269-75.
22. Luo JD, Zhang WW, Zhang GP, Guan JX, Chen X. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol 1999;26:903-8.
23. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997;272:31725-9.
24. Scherrer-Crosbie M, Ullrich R, Bloch KD, Nakajima H, Nasseri B, Aretz HT, Lindsey ML, Vancon AC, Huang PL, Lee RT, Zapol WM, Picard MH. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 2001;104:1286-91.
25. Jones SP, Greer JJ, van Haperen R, Duncker DJ, de Crom R, Lefer DJ. Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc Natl Acad Sci U S A 2003;100:4891-6.
26. Kaneta S, Satoh K, Kano S, Kanda M, Ichihara K. All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis 2003;170:237-43.
27. Walter DH, Dimmeler S, Zeiher AM. Effects of statins on endothelium and endothelial progenitor cell recruitment. Semin Vasc Med 2004;4:385-93.
28. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, Diaz C, Hernandez G, Egido J. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998;83:490-500.
29. van Vliet AK, van Thiel GC, Huisman RH, Moshage H, Yap SH, Cohen LH. Different effects of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochim Biophys Acta 1254;1:105-11.
30. Shimizu K, Aikawa M, Takayama K, Libby P, Mitchell RN. Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation 2003;108:2113-20.
31. Yokoyama K, Ishibashi T, Ohkawara H, Kimura J, Matsuoka I, Sakamoto T, Nagata K, Sugimoto K, Sakurada S, Maruyama Y. HMG-CoA reductase inhibitors suppress intracellular calcium mobilization and membrane current induced by lysophosphatidylcholine in endothelial cells. Circulation 2002;105:962-7.